H
Hugo M. Horlings
Researcher at Netherlands Cancer Institute
Publications - 129
Citations - 18740
Hugo M. Horlings is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 46, co-authored 106 publications receiving 15805 citations. Previous affiliations of Hugo M. Horlings include BC Cancer Agency & University of Amsterdam.
Papers
More filters
Journal ArticleDOI
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer
Fabien Reyal,Fabien Reyal,Martin H. van Vliet,Martin H. van Vliet,Nicola J. Armstrong,Hugo M. Horlings,Karin E. de Visser,Marlen Kok,Andrew E. Teschendorff,S. Mook,Laura van 't Veer,Carlos Caldas,Rémy Salmon,Marc J. van de Vijver,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels +15 more
TL;DR: It is revealed that the nine signatures perform similarly but exhibit a large degree of discordance in prognostic group assignment, which indicates that proliferation is a common cellular process, but that other functional categories are also enriched and show independent prognostic ability.
Journal ArticleDOI
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Alexandra M Pietersen,Hugo M. Horlings,Michael Hauptmann,Anita Langerød,Abderrahim Ajouaou,Paulien Cornelissen-Steijger,L. Wessels,Jos Jonkers,Marc J. van de Vijver,Maarten van Lohuizen +9 more
TL;DR: The data highlight that whereas EZH2 and BMI1 may function in a 'linear' pathway in normal development, their overexpression has different functional consequences for breast tumourigenesis.
Journal ArticleDOI
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.
Ian J. Majewski,Ian J. Majewski,Lorenza Mittempergher,Nadia M Davidson,Astrid Bosma,Stefan M. Willems,Hugo M. Horlings,Iris de Rink,Liliana Greger,Gerrit K. J. Hooijer,Dennis Peters,Petra M. Nederlof,Ingrid Hofland,Jeroen de Jong,Jelle Wesseling,Roelof J.C. Kluin,Wim Brugman,Ron M. Kerkhoven,Frank Nieboer,Paul Roepman,Annegien Broeks,Thomas Muley,Jacek Jassem,Jacek Niklinski,Nico van Zandwijk,Alvis Brazma,Alicia Oshlack,Michel M. van den Heuvel,René Bernards +28 more
TL;DR: This approach provides a global overview of kinase fusion events, irrespective of the identity of the fusion partner, and identifies numerous genetic alterations impacting fibroblast growth factor receptor 3 in lung squamous cell carcinoma and a novel ALK fusion partner in lung adenocarcinoma.
Journal ArticleDOI
Molecular profiles of progesterone receptor loss in human breast tumors
Chad J. Creighton,C. Kent Osborne,Marc J. van de Vijver,Marc J. van de Vijver,John A. Foekens,Jan G. M. Klijn,Hugo M. Horlings,Dimitry S.A. Nuyten,Yixin Wang,Yi Zhang,Gary C. Chamness,Susan G. Hilsenbeck,Adrian V. Lee,Rachel Schiff +13 more
TL;DR: ER+/PR− tumors as defined by RNA profiling represent a distinct subset of breast cancer with aggressive features and poor outcome, despite being clinically ER+.
Journal ArticleDOI
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Qing-Bai She,Qing-Bai She,Sofia K. Gruvberger-Saal,Sofia K. Gruvberger-Saal,Matthew Maurer,Yilun Chen,Mervi Jumppanen,Tao Su,Meaghan Dendy,Ying Ka Ingar Lau,Lorenzo Memeo,Hugo M. Horlings,Marc J. van de Vijver,Jorma Isola,Hanina Hibshoosh,Neal Rosen,Ramon Parsons,Lao H. Saal,Lao H. Saal +18 more
TL;DR: This study emphasizes the importance of PI3K/PTEN pathway activity in ER-negative and basal-like breast cancer and supports the future clinical evaluation of combining EGFR andPI3K pathway inhibitors for the treatment of BLBC.